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Background—Antiretroviral therapy (ART) initiation is now recommended irrespective of CD4 
count. However data on the relationship between CD4 count at ART initiation and loss to follow-
up (LTFU) are limited and conflicting.
Methods—We conducted a cohort analysis including all adults initiating ART (2008–2012) at 
three public sector sites in South Africa. LTFU was defined as no visit in the 6 months before 
database closure. The Kaplan-Meier estimator and Cox's proportional hazards models examined 
the relationship between CD4 count at ART initiation and 24-month LTFU. Final models were 
adjusted for demographics, year of ART initiation, programme expansion and corrected for 
unascertained mortality.
Results—Among 17 038 patients, the median CD4 at initiation increased from 119 (IQR 54–
180) in 2008 to 257 (IQR 175–318) in 2012. In unadjusted models, observed LTFU was associated 
with both CD4 counts <100 cells/μL and CD4 counts ≥300 cells/μL. After adjustment, patients 
with CD4 counts ≥300 cells/μL were 1.35 (95% CI 1.12 to 1.63) times as likely to be LTFU after 
24 months compared to those with a CD4 150–199 cells/μL. This increased risk for patients with 
CD4 counts ≥300 cells/μL was largest in the first 3 months on treatment. Correction for 
unascertained deaths attenuated the association between CD4 counts <100 cells/μL and LTFU 
while the association between CD4 counts ≥300 cells/μL and LTFU persisted.
Conclusions—Patients initiating ART at higher CD4 counts may be at increased risk for LTFU. 
With programmes initiating patients at higher CD4 counts, models of ART delivery need to be 
reoriented to support long-term retention.
Introduction
Access to antiretroviral therapy (ART) has improved considerably in the past decade. By the 
end of 2013, 12.9 million people globally were receiving ART.1 Programmes have increased 
in size and expanded access with patients initiating ART at higher CD4 counts. In all 
regions, median CD4 counts at ART initiation are increasing.2
Increases in CD4 counts at ART initiation reflect progressive changes in WHO guidelines. 
Prior to 2010, ART was recommended for adults with CD4 counts below 200 cells/μL 
irrespective of WHO clinical stage.3 The CD4 threshold was changed in 2010 to 350 cells/
μL4 and raised further in the 2013 guidelines to include all patients with a CD4 count of 500 
cells/μL or less.5 In September 2015, the WHO announced ART should be initiated in all 
people living with HIV at any CD4 count.6 The global trend towards earlier initiation of 
ART is the result of advances in science, improvements in ART drugs and developments in 
the practice of HIV care.7
Despite the potential benefits of earlier ART initiation, its impact on patient behaviour and 
resulting loss to follow-up (LTFU) is not well understood. LTFU in ART programme 
represents a considerable challenge and removing the CD4 threshold increases the number 
of eligible patients for ART.8–10 A critical obstacle to assessing associations with LTFU is 
determining whether a patient considered LTFU is truly lost or an unascertained death. A 
valid measure of LTFU is particularly important when assessing the association between 
CD4 and LTFU since lower CD4 counts are related to mortality.1112 The limited data 
available on the relationship between CD4 counts at ART initiation and LTFU is conflicting. 
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In previous research, higher CD4 counts are associated with both an increased1314 and 
decreased risk of LTFU.1516 Given this conflicting evidence, the need to assess adherence 
and retention in people initiating ART at higher CD4 counts has been highlighted.5
We investigated the relationship between CD4 counts at ART initiation and LTFU in the first 
24 months on treatment among adults initiating ART between 2008 and 2012 in the South 
African cohorts of the International epidemiologic Databases to Evaluate AIDS—Southern 
Africa (IeDEA-SA) collaboration. We hypothesised that after adjustment for individual (age, 
sex, year of ART initiation) and programme (cohort size, rate of expansion) factors, patients 
initiating ART at higher CD4 counts may be at an increased risk of LTFU.
Methods
Study design, population and eligibility criteria
We conducted a multicentre, retrospective cohort analysis using data from the IeDEA-SA 
collaboration. The collaboration has been described in detail previously.1718 Briefly, patients 
were included in the analysis if they were ART naïve, 16 years of age or older, not pregnant 
at ART initiation, initiated ART in 2008 or later, and had a CD4 count measure available at 
ART initiation. Analysis was restricted to patients who had a minimum of 6 months of 
follow-up and outcomes were restricted to the first 24 months of treatment. For the main 
analysis, only patients with a recorded South African civil identification (ID) number were 
included and thus our main analysis included data from three public sector sites (Hlabisa 
(cohort 1), Khayelitsha (cohort 2), Themba Lethu (cohort 3)) providing ART free of charge 
to adults in three South African provinces (Gauteng, Kwa-Zulu Natal and the Western 
Cape).
Data from an additional two cohorts (Gugulethu and Tygerberg) that did not collect IDs 
were included in the sensitivity analyses.
Variables and definitions
At ART initiation, individual demographics (sex and age) and measures of disease severity 
(CD4 count and WHO stage) were assessed. Two variables were generated to quantify 
programme expansion: programme size and the rate of programme scale up. For each 
cohort, the number of ART patients receiving care at the end of the calendar year of ART 
initiation was defined as a measure of programme size.10 The rate of programme scale up 
was estimated as the rank of the patient divided by the number of months that the 
programme had been providing ART. For example, the 200th patient enrolling in the 10th 
month of the programme would have a rate of scale up of 20 (200/10).10
Patients were defined as LTFU if they were not known to be dead or transferred out, and had 
no visit in the 6 months before the database closure. The date of LTFU was defined as the 
date of last contact. For patients who had initiated ART and did not return, 1 day of follow-
up was added so that they would be included in the survival analysis.19 Patients who were 
dead or transferred out were censored at the date of death or transfer.
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Corrected estimates of LTFU were made through linkage by ID within the National 
Population Register (NPR) of the South African Department of Home Affairs. Patients 
previously defined as LTFU were reclassified as dead if they had a date of death in the NPR 
within 3 months of their date of LTFU.20 Corrected estimates, therefore, reflect 
incorporating data from the NPR, ‘corrected LTFU’, whereas uncorrected estimates are 
based on participant attendance, ‘observed LTFU’.
Data analysis
Patient characteristics at ART initiation were compared by CD4 count categories at ART 
initiation and reported with appropriate summary statistics (proportions, medians and IQR). 
The Kaplan-Meier (KM) estimator was used to obtain estimates of the proportion of those 
LTFU (observed or corrected) and reported every 6 months. KM curves were plotted and 
presented by CD4 levels at ART initiation.
To assess the association between CD4 count at ART initiation and the risk of LTFU, a 
series of Cox's proportional hazards regression models were fitted. CD4 count at ART 
initiation was modelled as a categorical variable in 50 cells/μL increments up to ≥300 cells/
μL. The reference category used was a CD4 count between 150 and 199 cells/μL to facilitate 
examination of possible trends at lower and higher CD4 counts. All models were stratified 
by cohort. Separate models were used to assess observed and corrected LTFU. The 
proportional hazards of LTFU were modelled overall (0–24 months) and separately for 0–3, 
3–12 and 12–24 months after ART initiation. Schoenfeld residuals were used to confirm the 
proportional hazards assumption. Adjusted models included other variables at ART 
initiation: year of ART initiation, sex, age, cohort size and rate of scale up. In the main 
analysis, WHO status was excluded because of the large amount of missing data (36% 
missing).
A series of sensitivity analyses were conducted to explore the impact of missing data and 
non-differential censoring. To address missing IDs, inverse probability weighting was done 
whereby patients with IDs who were not alive and in care were weighted to represent all 
patients who were not alive and in care.21–24 Weighting of patients with IDs was determined 
as the probability of being in a cohort with IDs multiplied by the modelled probability of 
having a recorded ID (based on cohort, year of ART initiation, final outcome and CD4 count 
at ART initiation). Multiple imputation using chained equation methods25 was used to 
impute missing CD4 counts at ART initiation. We multiply imputed CD4 counts (5 times) 
and the imputation models included the same variables as the Cox models. Competing risk 
regression was employed to model time to LTFU taking the competing event of death into 
account.10
Data were analysed using STATA V.13.0 (STATA Corporation, College Station, Texas, 
USA). Ethical approval was received from the relevant institutions at each of the sites and 
the University of Cape Town Human Research Ethics Committee.
Grimsrud et al. Page 4
J Epidemiol Community Health. Author manuscript; available in PMC 2016 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Results
The main analysis included 17 038 adults who initiated ART between January 2008 and 
June 2012 in one of three cohorts (table 1). Median CD4 at ART initiation increased with 
each successive calendar year from 119 cells/μL in 2008 (IQR 54–180) to 257 cells/μL in 
2012 (IQR 175–318). The proportion of patients in WHO stage IV at ART initiation was 
25%, 17%, 9%, 8% and 17% for patients in CD4 groups <50, 50–99, 100–199, 200– 299 
and ≥300 cells/μL, respectively. The median programme size by individuals was almost 10 
000 patients (median 9846, IQR 7588–11 074) with an average of 160 new patients initiating 
treatment every month (median 167, IQR 132–192).
Proportion of LTFU
A cumulative total of 6%, 10%, 14% and 17% of patients were observed to be LTFU at 6, 
12, 18 and 24 months, respectively. Observed proportions of LTFU differed by CD4 count at 
ART initiation (figure 1A). The highest proportion of observed LTFU was seen in patients 
with CD4 counts at ART initiation <100 or ≥300 cells/μL, and the lowest proportions in 
patients initiating ART between 100 and 200 cells/μL. Rates of observed LTFU also varied 
by cohort with 12-month observed LTFU ranging from 7% to 13% and 24-month observed 
LTFU from 12% to 21%. Consistent across all cohorts were high proportions of observed 
LTFU in patients with CD4 counts below 50 cells/μL. Proportions of observed LTFU were 
highest in patients with <50 and ≥300 cells/μL CD4 counts at ART initiation when stratified 
by year of ART initiation (results not shown).
After accounting for unascertained deaths, LTFU decreased over time with corrected 
cumulative LTFU estimated at 5%, 8%, 11% and 14% at 6, 12, 18 and 24 months, 
respectively (figure 2). Correcting for deaths accounted for a relative reduction in LTFU of 
between 16% (24 months) and 30% (6 months) (results not shown). Corrected LTFU 
differed by CD4 count at ART initiation (figures 1B and 2). Proportions of corrected LTFU 
appeared similar among all patients initiating ART with CD4 counts <200 cells/μL, and 
were highest in patients initiating ART at a CD4 count ≥300 cells/μL (figure 1B). This was 
observed in all cohorts. As with observed LTFU, corrected LTFU varied by cohort. 12-
month LTFU ranged from 7% to 10% and 24-month LTFU from 12% to 18% (results not 
shown).
Risk of LTFU
Overall, an increased risk of observed LTFU was seen in patients initiating ART with <100 
cells/μL and CD4 counts ≥300 cells/ μL compared to patients with a CD4 count between 150 
and 199 cells/μL (figure 3 and online supplementary appendix 1). After adjusting for 
demographics, year of ART initiation, programme size, and rate of scale up, the increased 
risk of observed LTFU persisted for those with a CD4 count <100 and ≥300 cells/μL at ART 
initiation compared to patients with a CD4 count between 150 and 199 cells/μL (table 2 and 
online supplementary appendix 1).
Patients initiating ART with CD4 counts ≥300 cells/μL were at an increased risk of being 
LTFU over 24 months of ART (table 2). Patients initiating ART with a CD4 count ≥300 
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cells/ μL were 35% more likely to be LTFU after 24 months of ART compared to patients 
with a CD4 count between 150 and 199 cells/μL at ART initiation (adjusted HR 1.35, 95% 
CI 1.12 to 1.63). The risk of LTFU was largest in the first year on ART (table 2). After 12 
months of treatment, no significant association was observed between CD4 count at ART 
initiation and corrected LTFU. The increased risk of observed LTFU among patients with 
lower CD4 counts at ART initiation was attenuated by unascertained deaths and did not 
persist in crude or adjusted models of corrected LTFU (figure 3 and table 2).
The association between CD4 count at ART initiation and LTFU was assessed separately for 
each of the three cohorts (see online supplementary appendix 2). The results in cohorts 1 and 
2 were very similar to the overall associations observed between CD4 count and LTFU. For 
cohort 3, patients with CD4 counts <100 cells/μL and with CD4 counts between 200 and 
249 cells/ μL had a decreased risk of LTFU compared to patients initiating ART with CD4 
counts between 150 and 199 cells/μL. In this cohort, a limited number of patients initiated 
treatment at CD4 counts above 200 cells/μL (n<500) and later than 2009 (n<50). Median 
CD4 count in cohort 3 was 105 compared to 142 and 151 in the other two cohorts, 
respectively.
Subgroup analyses were done to assess the association between CD4 count at ART initiation 
and LTFU by year of ART initiation, sex and age (see online supplementary appendix 3). In 
each year of ART initiation, an increased hazard of LTFU was observed among patients 
initiating ART with a CD4 count of ≥300 cells/μL compared to patients initiating ART 
between 150 and 199 cells/μL. In final models, women were 35% more likely (aHR 1.35, 
95% CI 1.09 to 1.68) and men were 24% more likely (aHR 1.24, 95% CI 0.84 to 1.82) to be 
LTFU if they initiated ART with a CD4 count ≥300 cells/μL compared to patients initiating 
ART between 150 and 199 cells/μL. An increased risk of LTFU was observed in patients 25 
years and older with a CD4 count ≥300 cells/μL compared to patients initiating ART for 
CD4 counts between 150 and 199 cells/μL. No association between a CD4 count ≥300 cells/
μL and LTFU was observed in patients <25 years of age (HR 0.99, 95% CI 0.61 to 1.58).
Of the five cohorts assessed for eligibility, two cohorts did not collect IDs. There were 26 
466 patients with missing data (CD4 counts were missing in 5457 patients at ART initiation, 
4828 did not have a recorded ID, and 16 161 did not have a CD4 count or recorded ID). 
Characteristics of patients with and without IDs are summarised in online supplementary 
appendix 4. In sensitivity analyses accounting for missing data, the association between 
higher CD4 count at ART initiation and increased risk of early LTFU persisted, similar to 
the main results. When inverse probability weighting was used to account for missing IDs, 
patients with a CD4 count ≥300 cells/μL at ART initiation were 55% more likely to be 
LTFU in the first 3 months of ART (95% CI 0.94 to 2.55) (see online supplementary 
appendix 5). This association is slightly reduced compared to the results in the main analysis 
(aHR 1.68, 95% CI 1.15 to 2.45) (table 2). Similarly, in multiple imputation models 
including patients with missing CD4 counts, a CD4 count ≥300 cells/μL was associated with 
a 50% increase in LTFU in the first 3 months of ART (95% CI 1.04 to 2.18) (see online 
supplementary appendix 6). The competing risk analysis yielded similar conclusions to the 
main results (see online supplementary appendix 7).
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Discussion
Our analyses demonstrate that patients initiating ART at CD4 counts ≥300 cells/μL are at an 
increased risk of LTFU in the first 24 months on ART. The increased risk of LTFU among 
patients with higher CD4 counts at ART initiation was observed both with and without 
correction for unascertained deaths and persisted after adjustment for individual factors and 
measures of programme expansion. The greatest increase in risk of LTFU for patients 
initiating with higher CD4 counts was in the first year on treatment. While low CD4 count at 
ART initiation was associated with increased risk LTFU, correction for unascertained deaths 
removed this association.
Our finding that CD4 counts ≥300 cells/μL are associated with higher risk of LTFU is 
aligned with previous findings1314 from smaller, individual studies. In Uganda, a tracing 
study of patients LTFU found higher rates of LTFU among those with CD4 counts ≥250 
cells/μL. CD4 counts ≥250 cells/μL were also associated with treatment interruptions.26 
Conversely, other studies have found higher CD4 counts were associated with reduced 
LTFU.1627 However, limited data were available on patients with CD4 counts ≥300 cells/μL 
and LTFU was not corrected for unascertained deaths.
We can speculate as to why patients who initiate ART at higher CD4 counts may be at an 
increased risk of being lost to care. ART services have been designed to support acutely ill 
HIV patients with lower CD4 counts. Patients who initiate ART at higher CD4 counts 
without an illness experience are not catered for in the services, and they may not experience 
any immediate benefits of ART and thus, disengage from care early.13 The association 
between CD4 counts of ≥300 cells/μL and risk of LTFU was highest in the first year on 
treatment, especially in the first 3 months. This suggests interventions are needed to change 
how patients with higher CD4 cell counts are initiated onto ART. Given the range of CD4 
counts at which patients are now initiating ART, models of ART provision that triage 
patients at initiation based on CD4 count should be considered to provide more tailored 
support. In addition, pretherapy counselling should be updated to address the distinct 
challenges faced by patients initiating treatment at higher CD4 counts.28 Beyond ART 
initiation, patients with higher CD4 counts at ART initiation may benefit from receiving 
ART outside of traditional facility-based models by accessing ART in community-based 
models of care.
Our finding that patients initiating ART with higher CD4 counts are at greater risk of being 
LTFU is relevant as countries align national ART guidelines with the 2015 WHO 
guidelines.56 Given the advances in ART drugs and the evidence that earlier ART can 
benefit both the individual and the population; the question is less about when patients 
should initiate ART, but how. It is paramount that the change in ART eligibility criteria is 
accompanied by health system adaptations. We need to adapt where and how patients with 
higher CD4 counts are initiated into ART given the increased risk of LTFU in the first year 
on treatment. We are reliant on a limited number of service delivery models that may not 
provide the most appropriate care for our evolving ART programmes. Furthermore, 
innovative models of care are needed to improve long-term retention of patients. It is also 
apparent that we are going to need a variety of models; models that can coexist and have 
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strong referral mechanisms to meet the different needs of increasingly heterogeneous 
populations accessing ART.29 Options for populations who currently have inequitable access 
to ART, including men, older populations, and underserved populations, are also needed.
We are uniquely positioned to assess the association between a range of CD4 counts and 
LTFU. With data from multiple cohorts, we could look at more patients at higher CD4 
thresholds than previous research. The challenge faced by many ART cohort analyses of 
differentiating risk factors for corrected LTFU from risk factors for unascertained deaths is 
overcome through linkage with the NPR. The quality of the NPR is very high with nearly 
90% of adult deaths captured.30 A valuable finding provided through linkage was that no 
significant association between lower CD4 counts and corrected LTFU was observed. This 
suggests that the association in uncorrected models was an artefact of unascertained 
mortality. That the association between CD4 counts ≥300 cells/μL and LTFU remained after 
linkage gives weight to our findings. Novel to our findings is that the association persisted 
after adjusting for measures of programme expansion. Therefore, increases in LTFU are not 
necessarily the result of deteriorating quality of care as ART programmes have expanded.31 
Changes to the profile of patients at ART initiation, including a greater number of patients at 
higher CD4 cell counts without an illness experience, are related to increased LTFU, a result 
of the model of ART delivery not being appropriate for all patients accessing ART.
Our study should be considered in light of a number of limitations. Data were missing on a 
number of key variables, including CD4 counts at ART initiation and South African civil ID 
numbers. We chose to exclude patients with missing CD4 levels postulating that missing 
data was likely to be related to administrative and clerical errors and is, therefore, likely to 
be missing completely at random (ie, not related to particular covariates). In sensitivity 
analyses, models with imputed missing CD4 counts and weighted for missing IDs yielded 
consistent findings to the main results. Previous analyses also found patients with and 
without IDs were comparable.23 We also observed differences in the relationship between 
CD4 count at ART initiation and the risk of LTFU when assessed by cohort. Although we 
were unable to explore explanations for such differences, it is plausible that these may be 
due to disparities between sites, such as rate and size of programme scale up, and therefore 
variations in the quality of care provided. Data on patients with CD4 counts ≥300 cells/μL 
were limited as the change in South African guidelines for initiation of patients with a CD4 
count <350 cells/μL was only announced in August 2011.32 Therefore, patients with higher 
CD4 counts in our analysis may have been initiated for other clinical reasons and not be 
representative of patients initiating ART at higher CD4 counts. In this analysis, 17% of 
patients initiating with a CD4 count ≥300 cells/μL were in WHO stage IV. From a 
programmatic perspective, our analysis is limited to reporting on LTFU after ART initiation 
and ignores that a considerable proportion of the patients determined to be LTFU may be 
treatment interrupters who will re-engage with ART services at a later date.31
Our study found that patients who initiate ART with a CD4 count ≥300 cells/μL are at an 
increased risk of being LTFU after 24 months on treatment compared to patients initiating 
with a CD4 count between 150 and 199 cells/μL. Acknowledging the potential benefits of 
early ART initiation, further research is needed on how to successfully support patients who 
initiate treatment at higher CD4 counts. This is especially relevant as countries transition to 
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‘Treat All’ offering ART to everyone living with HIV. It is widely acknowledged that the 
greatest threat to the long-term success of the rapidly expanding ART programmes is 
ensuring adherence and retention in care.33 Given these challenges, now is the time to 
innovate our health systems to more effectively and efficiently deliver ART.
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What is already known on this subject
Data on the relationship between CD4 count at the time of initiating antiretroviral therapy 
and the risk of loss to follow-up are limited and inconsistent. Few studies have large 
numbers of patients starting antiretroviral therapy at higher CD4 counts. Also, estimates 
of loss to follow-up can be invalid if there are high rates of unreported deaths. We were 
able to combine data from multiple sites and correct for unreported deaths through 
linkage with a death registry, thus having sufficient data to assess the relationship 
between higher CD4 counts and an accurate measure of loss to follow-up.
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What this study adds
We now have evidence that patients who have higher CD4 counts when they start 
antiretroviral treatment may be more likely to be lost to the treatment programme. This 
finding suggests we should reconsider how health systems can best support patients who 
are relatively well when they initiate treatment and highlights the need for further 
research as treatment programmes expand access to all HIV-positive people.
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Figure 1. 
Kaplan-Meier plots showing observed and corrected 24 months loss to follow-up (LTFU) by 
CD4 count at ART initiation. (A) Observed LTFU by CD4 count at antiretroviral therapy 
(ART) initiation 0–24 months follow-up. (B) Corrected LTFU by CD4 count at ART 
initiation 0–24 months follow-up.
Grimsrud et al. Page 13
J Epidemiol Community Health. Author manuscript; available in PMC 2016 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. 
Corrected loss to follow-up from Kaplan-Meier estimates by CD4 count at antiretroviral 
therapy initiation.
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Figure 3. 
Adjusted 12-months log hazard ratios of observed and corrected loss to follow-up from 
Cox's proportional hazards models by CD4 count at antiretroviral therapy (ART) initiation. 
Adjusted for year of ART initiation, gender, age, programme size and rate of expansion.
Grimsrud et al. Page 15
J Epidemiol Community Health. Author manuscript; available in PMC 2016 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Grimsrud et al. Page 16
Ta
bl
e 
1
Pa
tie
nt
 c
ha
ra
ct
er
ist
ic
s a
m
on
g 
17
 0
38
 a
du
lts
 in
iti
at
in
g 
pu
bl
ic
-s
ec
to
r a
nt
ir
et
ro
v
ir
al
 th
er
ap
y 
(A
RT
) b
y C
D4
 co
un
t a
t A
RT
 in
iti
at
io
n,
 2
00
8–
20
12
Ba
se
lin
e 
ch
ar
ac
te
ri
st
ic
C
D
4<
50
 ce
lls
/μ
L 
(n
=3
14
5)
C
D
4 
50
–9
9 
ce
lls
/μ
L 
(n
=2
93
4)
C
D
4 
10
0–
19
9 
ce
lls
/μ
L 
(n
=6
85
0)
C
D
4 
20
0–
29
9 
ce
lls
/μ
L 
(n
=2
95
4)
C
D
4≥
30
0 
ce
lls
/μ
L 
(n
=1
15
5)
To
ta
l (n
=1
7 0
38
)
Co
ho
rt
 
H
la
bi
sa
 (1
)
14
40
 (4
5.8
)
14
37
 (4
9.0
)
33
64
 (4
9.1
)
11
90
 (4
0.3
)
85
9 
(74
.4)
82
90
 (4
8.7
)
 
K
ha
ye
lit
sh
a 
(2)
84
1 
(26
.7)
92
5 
(31
.5)
24
06
 (3
5.1
)
13
98
 (4
7.3
)
19
4 
(16
.8)
57
64
 (3
3.8
)
 
Th
em
ba
 L
et
hu
 (3
)
86
4 
(27
.5)
57
2 
(19
.5)
10
80
 (1
5.8
)
36
6 
(12
.4)
10
2 
(8.
8)
29
84
 (1
7.5
)
G
en
de
r
 
Fe
m
al
e
17
00
 (5
4.1
)
17
67
 (6
0.2
)
46
96
 (6
8.6
)
21
72
 (7
3.5
)
90
8 
(78
.6)
11
 2
43
 (6
6.0
)
A
ge
 (y
ea
rs)
 
M
ed
ia
n 
(IQ
R)
35
.2
 (3
0.0
–4
1.7
)
35
.6
 (2
9.9
–4
2.4
)
35
.3
 (2
9.8
–4
2.7
)
34
.5
 (2
8.9
–4
1.3
)
35
.3
 (2
9.0
–4
3.2
)
35
.2
 (2
9.6
–4
2.2
)
 
 
16
–2
4
19
7 
(6.
3)
20
2 
(6.
9)
52
7 
(7.
7)
26
3 
(8.
9)
13
1 
(11
.3)
13
20
 (7
.8)
 
 
25
–3
4
13
51
 (4
3.0
)
11
85
 (4
0.4
)
28
01
 (4
0.9
)
12
82
 (4
3.4
)
44
0 
(38
.1)
70
59
 (4
1.4
)
 
 
35
–4
4
10
72
 (3
4.1
)
10
00
 (3
4.1
)
21
66
 (3
1.6
)
94
9 
(32
.1)
34
4 
(29
.8)
55
31
 (3
2.5
)
 
 
≥4
5
53
5 
(16
.7)
54
7 
(18
.6)
13
56
 (1
9.8
)
46
0 
(91
5.6
)
24
0 
(20
.8)
31
28
 (1
8.4
)
Ye
ar
 o
f A
RT
 in
iti
at
io
n
 
20
08
10
89
 (3
4.6
)
91
8 
(31
.3)
19
77
 (2
8.9
)
60
1 
(20
.4)
13
2 
(11
.4)
47
17
 (2
7.7
)
 
20
09
10
61
 (3
3.7
)
93
8 
(32
.0)
21
65
 (3
1.6
)
78
1 
(26
.4)
19
9 
(17
.2)
51
44
 (3
0.2
)
 
20
10
61
5 
(19
.6)
66
3 
(22
.6)
16
32
 (2
3.8
)
80
8 
(27
.4)
30
9 
(26
.8)
40
27
 (2
3.6
)
 
20
11
35
8 
(11
.4)
38
6 
(13
.2)
98
0 
(14
.3)
61
5 
(20
.8)
36
6 
(31
.7)
27
05
 (1
5.9
)
 
20
12
22
 (0
.7)
29
 (1
.0)
96
 (1
.4)
14
9 
(5.
0)
14
9 
(12
.9)
44
5 
(2.
6)
W
H
O
 st
ag
e
 
I a
nd
 II
34
2 
(18
.9)
59
5 
(32
.1)
22
60
 (5
0.1
)
12
09
 (5
5.6
)
32
1 
(49
.8)
47
27
 (4
3.0
)
 
II
I
10
11
 (5
5.9
)
93
8 
(50
.6)
18
38
 (4
0.7
)
79
3 
(36
.5)
21
7 
(33
.7)
47
97
 (4
3.6
)
 
IV
45
6 
(25
.2)
32
1 
(17
.3)
41
4 
(9.
2)
17
3 
(8.
0)
10
6 
(16
.5)
14
70
 (1
3.4
)
 
M
iss
in
g
13
36
 (4
2.3
)
10
80
 (3
6.8
)
23
38
 (3
4.1
)
77
9 
(26
.4)
51
1 
(44
.2)
60
44
 (3
5.5
)
Co
ho
rt 
siz
e 
at
 in
iti
at
io
n 
(pa
tie
nts
)
 
<
75
00
44
1 
(14
.0)
46
7 
(15
.9)
96
8 
(14
.1)
33
9 
(11
.5)
23
3 
(20
.2)
24
48
 (1
4.4
)
 
75
00
–7
99
9
59
5 
(19
.0)
57
1 
(19
.5)
14
53
 (2
1.2
)
46
0 
(15
.6)
14
6 
(12
.6)
32
26
 (1
8.9
)
 
80
00
–9
89
9
81
2 
(25
.8)
62
9 
(21
.4)
13
87
 (3
0.2
)
43
0 
(14
.6)
21
8 
(18
.9)
34
76
 (2
0.4
)
 
99
00
–1
1 
49
9
78
1 
(24
.8)
73
0 
(24
.9)
16
39
 (2
3.9
)
84
3 
(28
.5)
13
7 
(11
.9)
41
30
 (2
4.2
)
J Epidemiol Community Health. Author manuscript; available in PMC 2016 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Grimsrud et al. Page 17
Ba
se
lin
e 
ch
ar
ac
te
ri
st
ic
C
D
4<
50
 ce
lls
/μ
L 
(n
=3
14
5)
C
D
4 
50
–9
9 
ce
lls
/μ
L 
(n
=2
93
4)
C
D
4 
10
0–
19
9 
ce
lls
/μ
L 
(n
=6
85
0)
C
D
4 
20
0–
29
9 
ce
lls
/μ
L 
(n
=2
95
4)
C
D
4≥
30
0 
ce
lls
/μ
L 
(n
=1
15
5)
To
ta
l (n
=1
7 0
38
)
 
≥1
1 
55
0
51
5 
(16
.4)
53
7 
(18
.3)
14
03
 (2
0.5
)
88
2 
(29
.9)
42
1 
(36
.5)
37
58
 (2
2.1
)
R
at
e 
of
 sc
al
e 
up
 (p
ati
en
ts/
mo
nth
)
 
<
13
0
73
5 
(23
.4)
72
7 
(24
.8)
15
73
 (2
3.0
)
33
4 
(11
.3)
17
2 
(15
.0)
35
42
 (2
0.8
)
 
13
0–
15
9
55
7 
(17
.7)
58
1 
(19
.8)
13
95
 (2
0.4
)
48
7 
(16
.5)
27
6 
(23
.9)
32
96
 (1
9.3
)
 
16
0–
17
9
52
5 
(16
.7)
52
4 
(17
.9)
14
38
 (2
1.0
)
74
5 
(25
.2)
28
4 
(24
.6)
35
16
 (2
0.6
)
 
18
0–
19
9
46
4 
(14
.8)
53
0 
(18
.1)
13
64
 (1
9.9
)
10
22
 (3
4.6
)
32
0 
(27
.7)
37
00
 (2
1.7
)
 
≥2
00
86
4 
(27
.5)
57
2 
(19
.5)
10
80
 (1
5.8
)
36
6 
(12
.4)
10
2 
(8.
8)
29
84
 (1
7.5
)
Ita
lic
s d
en
ot
es
 m
iss
in
g 
da
ta
.
J Epidemiol Community Health. Author manuscript; available in PMC 2016 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Grimsrud et al. Page 18
Table 2
HRs of overall, 0–3, 3–12 and 12–24 months corrected LTFU by CD4 count at ART 
initiation*
Overall (0–24 months) n=17 038 0–3 months n=17 038 3–12 months n=15 470 12–24 months n=12 728
Crude HR (cells/μL)
 <50 1.13 (0.98 to 1.30) 1.10 (0.81 to 1.49) 1.34 (1.07 to 1.68) 0.95 (0.75 to 1.20)
 50–99 1.01 (0.88 to 1.17) 1.14 (0.85 to 1.54) 1.05 (0.83 to 1.33) 0.92 (0.73 to 1.15)
 100–149 1.01 (0.88 to 1.17) 0.66 (0.47 to 0.94) 1.14 (0.92 to 1.43) 1.08 (0.87 to 1.33)
 150–199 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref)
 200–249 0.95 (0.82 to 1.11) 0.84 (0.60 to 1.18) 1.03 (0.81 to 1.32) 0.94 (0.74 to 1.19)
 250–299 1.38 (1.11 to 1.70) 1.56 (1.01 to 2.39) 1.39 (0.98 to 1.96) 1.27 (0.89 to 1.81)
 ≥300 1.62 (1.25 to 1.95) 1.95 (1.35 to 2.81) 1.70 (1.27 to 2.27) 1.34 (0.97 to 1.87)
Adjusted†—aHR (cells/μL)
 <50 1.08 (0.94 to 1.24) 1.07 (0.79 to 1.45) 1.30 (1.04 to 1.63) 0.89 (0.70 to 1.12)
 50–99 0.98 (0.85 to 1.13) 1.12 (0.83 to 1.52) 1.02 (0.81 to 1.29) 0.88 (0.70 to 1.11)
 100–149 1.00 (0.87 to 1.14) 0.66 (0.47 to 0.93) 1.12 (0.90 to 1.40) 1.06 (0.85 to 1.30)
 150–199 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref)
 200–249 0.89 (0.77 to 1.04) 0.80 (0.57 to 1.12) 0.95 (74 to 1.22) 0.90 (0.71 to 1.15)
 250–299 1.18 (0.95 to 1.46) 1.40 (0.90 to 2.16) 1.14 (0.80 to 1.62) 1.12 (0.89 to 1.60)
 ≥300 1.35 (1.12 to 1.63) 1.68 (1.15 to 2.45) 1.35 (1.00 to 1.81) 1.17 (0.84 to 1.64)
*All estimates are stratified by cohort.
†Adjusted for year of ART initiation, gender, age, programme size and rate of expansion.
ART, antiretroviral therapy; LTFU, loss to follow-up.
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